Compare InMode Ltd (INMD) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Repligen Corporation Common Stock — how do they compare? InMode Ltd trades at $14.29 (market cap $821.73M), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 13.8× InMode Ltd's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 28 Days and Repligen Corporation Common Stock for 0 Days on average.
| INMD | RGEN | |
|---|---|---|
Market Cap | $821.73M | $11.31B |
Volume | 337,645 | 1,216,919 |
Sector | Health | Health |
52-Week High | $16.62 | $194.57 |
52-Week Low | $12.76 | $102.87 |
Typical Hold Time | 28 Days | 0 Days |
Enterprise Value | $325.07M | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
InMode (INMD) trades at $14.305, up 0.03% today, with a bullish technical signal but mixed indicators. The company reported Q2 2026 revenue of $95.6M, consistent with the prior year, and maintains strong profitability with a net margin of 20.69%. Recent news includes the launch of Morpheus8 Cool and an unsolicited acquisition offer from Steel Partners at $16.75 per share.
The outlook is balanced: valuation appears attractive with a P/E of 11.8, but revenue stagnation and a recent earnings miss pose risks. Analyst sentiment is mixed with a slight hold bias. Upside potential exists from the acquisition offer and international growth, while cyclical softness and capital allocation concerns remain headwinds.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
